Popular blood pressure drug recalled
A pharma maker is voluntarily recalling several lots of a major heart medication. Here’s why.
A pharma maker is voluntarily recalling several lots of a major heart medication due to a carcinogenic impurity.
FDA and ScieGen Pharmaceuticals recalled antihypertensive drug irbesartan tablets in 75 mg, 150 mg, and 300 mg dosages at the consumer level. The 30-count and 90-count bottles were distributed nationwide to Westminster Pharmaceuticals and Golden State Medical Supply’s direct accounts.
Related: FDA warns about opioid-containing supplement
ScieGen discovered the presence of an impurity, N-nitrosodiethylamine (NDEA) in irbesartan API it received from Aurobindo Pharma Limited, used to manufacture the final product.
“This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC),” ScieGen said in a statement.
Related: FDA cracks down on websites selling iIllegal drugs
However, Sciegen has not received any reports of adverse events related to the product.
Although the irbesartan tablets were manufactured by ScieGen, they are labeled as Westminster Pharmaceuticals and Golden State Medical Supply, Inc [GSMS].
Expiration dates range from September 2019 to May 2020.
Read more: Asthma drug mix-up may pose safety risk
Trelegy and Breo Offer Incremental Improvement Over Generics
March 3rd 2025The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat patients with chronic obstructive pulmonary disease that are part of CMS's drug price negotiation program.
Read More
FDA Accepts sNDA for Zoryve Cream for Atopic Dermatitis Treatment in Young Children
February 26th 2025This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic dermatitis (AD) in children aged 2 to 5 years. The PDUFA target action date of October 13, 2025, is set for its decision on the application.
Read More
FDA Accepts BLA Resubmission for Follicular Lymphoma Drug, Odronextamab
February 26th 2025The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.
Read More
